Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy,
immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to
Humira®.
The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab
(manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis
of moderate and severe degree.